Imagine a patient with a rare condition in Greece who waits for years to access a new therapy. This is not an exception: reimbursement of innovative treatments in Greece is slow and only a small proportion of new therapies is available. The human cost is real. Yet biopharmaceutical science is advancing rapidly: international authorities classify…
Pharmaceutical innovation is more than a scientific or medical achievement—it is a strategic enabler for improving health outcomes, ensuring the sustainability of national healthcare systems, and driving economic growth. In Greece, this reality is becoming increasingly clear. With a population facing growing healthcare needs, limited resources, and mounting economic pressures, the integration of innovative therapies…
Biopharmaceutical research is advancing at an impressive pace, offering cutting-edge therapies that are transforming healthcare, altering the natural course of many severe diseases, and significantly improving patients’ quality of life. This progress makes pharmaceutical policy a decisive factor for the efficiency and resilience of the healthcare system, necessitating a structural revision that ensures innovation is…
“We want a Europe that does not just legislate, but truly innovates!” Ms. Labrina Barmpetaki, President of the PhARMA Innovation Forum (PIF), First Vice President of the Hellenic-American Chamber of Commerce, and Managing Director of AbbVie Greece, Cyprus & Malta, placed at the center of the 24th HealthWorld Conference, organized by the Hellenic-American Chamber of…
PhARMA Innovation (PIF) made a strong presence at the Bio3 Forum 2025 on Biotechnology, Bioinformatics & Bioeconomy, held on September 15–19 in Athens, under the theme “Fostering Collaboration in Industry & Academia.” The Forum served as a key reference point for the international scientific and business community, bringing together leading representatives from the pharmaceutical industry,…
A threat to patient access and public health PhARMA Innovation Forum (PIF) expresses its deep concern regarding the official data released by EKAPY (National Central Health Procurement Authority) – with a delay of more than a year – to our member companies. Once again, the figures reveal a complete derailment of the public budget for…
Innovation as a National Priority: The Key to a Sustainable Healthcare System At Astellas, we believe that innovation in biopharmaceuticals is not a luxury – it is a necessity in today’s ever-evolving healthcare landscape. Innovation has revolutionized the way we detect, treat, and manage diseases. From rare genetic disorders to chronic illnesses such as cancer,…
A Healthcare System that Encourages Innovation – A Shared Responsibility for Greece’s Future At Amgen Hellas, we serve a clear purpose: to improve patients’ quality of life by harnessing the power of science. We firmly believe that every citizen in Greece deserves equal and timely access to innovative treatments—therapies that not only extend life, but…
Greece in the Era of EHDS: A Dialogue on Innovation in Cancer Care The inaugural “My Data, Our Health” workshop, co-organized by Pharma Innovation Forum (PIF) and the Hellenic Cancer Federation (ELLOK), marked the beginning of a national dialogue on building a cohesive strategy for the responsible use of health data in Greece. As the…
Labrina Barmpetaki, President of PIF: “Harnessing medical data is essential for a fair and sustainable pharmaceutical policy.” Through targeted interventions and a clear, strategic message, PhARMA Innovation Forum (PIF) actively participated in the 6th Health Conference organized by Proto Thema. Labrina Barmpetaki, joined the panel discussion entitled “Shaping a National Pharmaceutical Policy: Prerequisites and Challenges.”…
